Skip Navigation

European Journal of Heart Failure 2005 7(5):874-877; doi:10.1016/j.ejheart.2005.03.002
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sanderson, J. E.
Right arrow Articles by Yu, C.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sanderson, J. E.
Right arrow Articles by Yu, C.M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society of Cardiology

Do metoprolol and carvedilol have equivalent effects on diurnal heart rate in patients with chronic heart failure?

John E. Sanderson*, Leata Y.C. Leung, Skiva K.W. Chan, Gabriel W.K. Yip, Jeffrey W.H. Fung and C.M. Yu

Division of Cardiology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 9th Fl Clinical Science Bldg Prince of Wales Hospital, Hong Kong SAR

* Corresponding author. Tel.: +852 2632 2064; fax: +852 2637 2396. E-mial address: john.sanderson{at}uhns.nhs.uk


   Abstract

Background: Carvedilol exerted a greater reduction in mortality than metoprolol tartrate in the Carvedilol or Metoprolol European Trial (COMET). However, it is unclear if the degree and time course of β1-blockade during a 24-h period was similar with each agent at the doses used. Therefore we analyzed 24-h ECG Holter recordings from a study which compared the long-term clinical efficacy of metoprolol tartrate to carvedilol in chronic heart failure patients using the same dosing regimen as in COMET.

Methods and results: Fifty-one patients with chronic heart failure with a mean LVEF 26+1.8% were randomized in a double-blind fashion to receive metoprolol tartrate 50 mg bid or carvedilol 25 mg bid. 24-h ECG monitoring (Holter) was performed at baseline, 12 weeks and 1 year. Adequate quality recordings for analysis were obtained from 43 subjects at baseline, 42 at 12 weeks and 29 subjects at 1 year. Both drugs produced a fall in average 24-h heart rate from baseline at 12 weeks and at 1 year: metoprolol 88+3 to 71+2 and 69+3 bpm; carvedilol 83+3 to 70+2 and 70+3 bpm respectively (all p<0.001). The pattern of suppression of heart rate during the 24-h period was similar for both drugs.

Conclusion: Metoprolol tartrate 50 mg bid and carvedilol 25 mg bid had similar effects on 24-h heart rate. This result suggests that the degree of β1-blockade produced by these two drugs in these doses is comparable and the superior survival effect of carvedilol compared to metoprolol seen in COMET is likely to be due to actions of carvedilol other than β1-blockade.

Key Words: Heart failure • Beta-blockers • Metoprolol • Carvedilol

Received August 20, 2004; Revised January 22, 2005; Accepted March 24, 2005


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J CARDIOVASC PHARMACOL THERHome page
T. J. Vittorio, R. Zolty, M. E. Kasper, R. M. Khandwalla, D. S. Hirsh, C.-H. Tseng, U. P. Jorde, and K. Ahuja
Differential Effects of Carvedilol and Metoprolol Succinate on Plasma Norepinephrine Release and Peak Exercise Heart Rate in Subjects With Chronic Heart Failure
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2008; 13(1): 51 - 57.
[Abstract] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.